4D Molecular Therapeutics (FDMT) Net Income (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Net Income data on file, last reported at -$94.9 million in Q1 2026.

• On a quarterly basis, Net Income fell 91.98% year-over-year to -$94.9 million in Q1 2026; TTM through Mar 2026 was -$252.7 million, a 13.1% decrease from a year earlier, with the FY2025 full-year figure at -$298.6 million, down 3.38% from the prior year.
• Net Income for Q1 2026 stood at -$94.9 million, down from $18.0 million in the prior quarter.
• Over the last five years, Net Income for FDMT reached as high as $18.0 million in Q4 2025 and fell as low as -$94.9 million in Q1 2026.
• Historically, Net Income has averaged -$48.4 million across 5 years, with a median of -$47.3 million in 2022.
• Across the five-year window, Net Income slumped 217.09% in 2022 and surged 135.65% in 2025, its largest moves.
• Year by year, Net Income stood at -$30.3 million in 2022, then fell by 9.21% to -$33.1 million in 2023, then tumbled by 52.85% to -$50.6 million in 2024, then jumped by 135.65% to $18.0 million in 2025, then plunged by 626.73% to -$94.9 million in 2026.
• Per Business Quant data, the three most recent Net Income figures were -$94.9 million in Q1 2026, $18.0 million in Q4 2025, and -$85.9 million in Q3 2025.